Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis

Diabetes, Obesity and Metabolism

Volumn 21, Issue 2, 2019, Pages 340-348

  Cahn, Avivit ^a,b   Melzer Cohen, Cheli ^b   Pollack, Rena ^a,b   Chodick, Gabriel ^b,c   Shalev, Varda ^b,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MACCABI HEALTHCARE SERVICES   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

cohort study; SGLT2 inhibitor; type 2 diabetes

Indexed keywords

CREATININE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ACUTE KIDNEY FAILURE; ADULT; ALL CAUSE MORTALITY; ARTICLE; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HOSPITALIZATION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROGNOSIS; RETROSPECTIVE STUDY; AGED; COMPLICATION; DIABETIC NEPHROPATHY; DRUG EFFECT; GLOMERULUS FILTRATION RATE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; RISK FACTOR;

ACUTE KIDNEY INJURY; AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITALIZATION; HUMANS; ISRAEL; MALE; MIDDLE AGED; MORTALITY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85054910738     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.13532     Document Type: Article

References (17)

1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128.
2. Wanner C, Inzucchi SE, Zinman B. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:1801-1802.
3. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.
4. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28:368-375.
5. US Food and Drug Administration. FDA drug and safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR) [article online]; 2016. https://www.fda.gov/Drugs/DrugSafety/ucm505860.htm. Accessed August 20, 2018.
6. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371:58-66.
7. Kohler S, Zeller C, Iliev H, Kaspers S. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther. 2017;34:1707-1726.
8. Tang H, Li D, Zhang J, et al. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19:1106-1115.
9. Zhang XL, Zhu QQ, Chen YH, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systemic review and meta-analysis with trial sequential analysis. J Am Heart Assoc. 2018;7:e007165.
10. Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40:1479-1485.
11. Perlman A, Heyman SN, Matok I, Stokar J, Muszkat M, Szalat A. Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: analysis of the FDA adverse event report system database. Nutr Metab Cardiovasc Dis. 2017;27:1108-1113.
12. Heerspink HJ, Johnsson E, Gause-Nilsson I, Cain VA, Sjostrom CD. Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers. Diabetes Obes Metab. 2016;18:590-597.
13. Zeni L, Norden AGW, Cancarini G, Unwin RJ. A more tubulocentric view of diabetic kidney disease. J Nephrol. 2017;30:701-717.
14. Anders HJ, Davis JM, Thurau K. Nephron protection in diabetic kidney disease. N Engl J Med. 2016;375:2096-2098.
15. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubulointerstitial function in diabetic kidneys. J Clin Med Res. 2016;8:844-847.
16. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39:1115-1122.
17. Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60:215-225.